Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.43
- Piotroski Score 5.00
- Grade Buy
- Symbol (ACLX)
- Company Arcellx, Inc.
- Price $74.38
- Changes Percentage (0.26%)
- Change $0.19
- Day Low $72.50
- Day High $74.71
- Year High $76.72
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $70.00
- High Stock Price Target $85.00
- Low Stock Price Target $32.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.03
- Trailing P/E Ratio -49.3
- Forward P/E Ratio -49.3
- P/E Growth -49.3
- Net Income $-70,690,000
Income Statement
Quarterly
Annual
Latest News of ACLX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why Arcellx (ACLX) Slipped in Q2
Baron Funds' "Baron Health Care Fund" Q2 2024 investor letter reported a 2.55% decline compared to benchmarks. The fund highlighted Arcellx, Inc. (NASDAQ:ACLX) as a top pick, with significant growth p...
By Yahoo! Finance | 1 month ago -
Insider Sale: CFO Michelle Gilson Sells 12,877 Shares of Arcellx Inc (ACLX)
Michelle Gilson, CFO of Arcellx Inc (NASDAQ:ACLX), sold 12,877 shares on June 26, 2024, now owning 6,915 shares. The biotech company focuses on cell therapies for cancer and autoimmune diseases....
By Yahoo! Finance | 2 months ago -
We Think Arcellx (NASDAQ:ACLX) Can Easily Afford To Drive Business Growth
Despite potential risks, shareholders can profit from buying a struggling business at the right price. For example, Arcellx has a long cash runway despite its negative free cash flow, indicating a goo...
By Yahoo! Finance | 2 months ago
